Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Divestments (2016 - 2017)

Soleno Therapeutics (SLNO) has disclosed Divestments for 2 consecutive years, with $717000.0 as the latest value for Q3 2017.

  • Quarterly Divestments rose 35750.0% to $717000.0 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was $716000.0 through Dec 2017, changed N/A year-over-year, with the annual reading at -$172000.0 for FY2018, 124.02% down from the prior year.
  • Divestments for Q3 2017 was $717000.0 at Soleno Therapeutics, up from $3000.0 in the prior quarter.
  • The five-year high for Divestments was $717000.0 in Q3 2017, with the low at -$6885.0 in Q4 2016.